Targets › SLC31A1
2 programs from 2 companies in 2 trials: 2 Phase 2; Oncology, Metabolic and endocrine; next expected readout Mar 2030.
[High affinity copper uptake protein 1]: Uniporter that mediates the transport of copper(1+) from the extracellular space to the cytoplasm, across the plasma membrane and delivers directly copper(1+) to specific chaperone such as ATOX1, via a copper(1+)- mediated transient interaction between the C-terminal domain and a copper(1+) chaperone, thus controlling intracellular copper(1+) levels. May function in…. (UniProt, O15431)
Open in Phaseline: the race on SLC31A1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Osaka University | Oxaliplatin Platinum-based DNA crosslinking agent | SLC31A1 | Phase 2 | Rectal Cancer | Mar 2030 |
| Universitas Indonesia | Zinc, Chromium, Vitamin C, and Copper Supplementation Combination mineral and vitamin supplement: zinc enhances insulin signaling and glucose me | SLC30A1, CREBBP, SLC31A1 | Phase 2 | PreDiabetes | – |
Rectal Cancer (1) PreDiabetes (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.